Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are compounds that do not occur in nature but have been widely used since World War II and persist indefinitely in the environment. They are present in the serum of Americans with median levels of 4 ng/mL and 21 ng/mL, respectively. PFOA has been positively associated with cholesterol in several studies of workers. A cross-sectional study of lipids and PFOA and PFOS was conducted among 46,294 community residents aged 18 years or above, who drank water contaminated with PFOA from a chemical plant in West Virginia. The mean levels of serum PFOA and PFOS in 2005-2006 were 80 ng/mL (median, 27 ng/mL) and 22 ng/mL (median, 20 ng/mL), respectively. All lipid outcomes except high density lipoprotein cholesterol showed significant increasing trends by increasing decile of either compound; high density lipoprotein cholesterol showed no association. The predicted increase in cholesterol from lowest to highest decile for either compound was 11-12 mg/dL. The odds ratios for high cholesterol (!240 mg/dL), by increasing quartile of PFOA, were 1.00, 1.21 (95% confidence interval (CI): 1.12, 1.31), 1.33 (95% CI: 1.23, 1.43), and 1.40 (95% CI: 1.29, 1.51) and were similar for PFOS quartiles. Because these data are cross-sectional, causal inference is limited. Nonetheless, the associations between these compounds and lipids raise concerns, given their common presence in the general population.
Both perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are perfluorinated compounds that have been found in the blood of virtually all tested Americans over the last decade (1). They do not occur naturally but were introduced in the environment after World War II.
PFOA is used to polymerize several types of fluoropolymers, which are used in a wide variety of industrial and consumer products. It has been used extensively as a surfactant in the manufacture of Teflon (DuPont, Wilmington, Delaware). PFOA does not break down once in the environment, leading to widespread buildup and bioaccumulation. The half-life of PFOA in humans is estimated to be about 3.8 years (2) . PFOA is not metabolized in the body; its tissue distribution in humans is unknown but, on the basis of experiments with rats, it is likely to be present primarily in the liver, kidney, and blood (3). It is not lipophilic, unlike chlorinated hydrocarbons. Most people tested in the United States have measurable PFOA in their serum, with a median level of 4 ng/mL (1), but PFOA is not formed naturally and the industrial or product routes of this exposure are not clear.
PFOA causes cancer of the testicles, liver, and pancreas in rodents, and there is some evidence that it also causes breast cancer in rodents (4) . It also causes fetal loss and low birth weight in mice (4) and has been shown to be weakly associated with lower birth weight in humans (5, 6) . It has been shown to be associated with increased liver enzymes in 3 occupational studies of workers (7) (8) (9) but not in 1 study of community residents exposed via contaminated drinking water (10) . It has also been found to be positively correlated with cholesterol in 5 occupational studies (7-9, 11, 12 ) and 1 community study (10) , although in several of these the relation was not statistically significant at the 0.05 level.
A putative mechanism by which PFOA might affect cholesterol in humans is not clear. However, as noted, there is evidence that PFOA is associated with increased liver enzymes, and the liver is an important site of cholesterol synthesis. It is also possible that an increase in fatty acids in the serum leads indirectly to higher cholesterol levels, with no impact on cholesterol production.
PFOS is another fluorocarbon that is widespread in the serum of US residents, with a median serum level of 21 ng/ mL, although as with PFOA the source of this exposure is not known (1) . Until recently, PFOS has been used in the manufacture of Scotchgard (3M Company, St. Paul, Minnesota), among other products. Its half-life has been estimated at 5.4 years (2). PFOS is also considered an animal carcinogen by the Environmental Protection Agency (4) . There is only 1 study of PFOS and cholesterol (13) , which found a significant (at the 0.05 level) positive association in a cross-sectional study of workers at 1 plant but not at another plant.
PFOA has been used in the manufacture of fluoropolymers at a chemical plant in Washington, West Virginia, since 1951. In 2001, a group of residents from the Ohio and West Virginia communities in the vicinity of the Washington Works plant filed a class-action lawsuit, alleging health damage due to contamination of human drinking water supplies with PFOA. The pretrial settlement of this lawsuit led to a baseline survey, called the C8 Health Project. This survey was conducted in 2005-2006 and gathered data from 69,000 Ohio and West Virginia residents or former residents who had lived, worked, or gone to school in 6 contaminated water districts surrounding the chemical plant. The C8 Health Project included blood draws and subsequent measurement of serum PFOA and serum PFOS, as well as clinical chemistry including lipids. PFOS has not been used at or emitted by the chemical plant.
The current study is an analysis of these data in adults aged 18 years or older who were not taking cholesterollowering medication, with a goal of determining whether there are associations between PFOA or PFOS and lipids. The exposure metric in this study is serum PFOA or PFOS measured in [2005] [2006] , and the outcomes are concurrent levels of lipids.
MATERIALS AND METHODS

Study participants
Study subjects participated in the C8 Health Project (2005) (2006) . The purpose of the C8 Health Project was to collect health data from residents covered under the legal settlement of a class action lawsuit, via written questionnaires and a battery of blood tests, including measurement of serum levels of PFOA and PFOS. Subjects were eligible to participate in the C8 Health Project if they had consumed public drinking water for at least 1 year before December 3, 2004 , supplied by any of 6 contaminated water districts, or from a small number of private wells known to be contaminated. The 6 water districts all had documented PFOA contamination of public water at !0.05 ng/mL. Subjects were eligible if they could document that they had lived, worked, or gone to school in a contaminated water district for at least 1 year. Figure 1 shows the 6 water districts. Subjects were compensated $400 if they filled out the extensive questionnaire and came to local survey stations to donate a blood sample (30-35 mL). The C8 Health Project collected data on 69,030 subjects, of whom 46,494 were 18 years or older and not taking cholesterol-lowering medication (19% of adults were taking such medication). It is not known what percentage of the eligible population participated, but it is believed to be the majority, given the high interest and the financial incentive. Using census data from 2005, we estimate that 81% of current residents aged 20 years or older participated in the C8 Health Project (14) .
The Emory University Institutional Review Board approved this study.
Laboratory methods
The analytical method for PFOA and PFOS used in this study has been described in detail previously (15, 16) . Briefly, the method utilizes liquid chromatography separation with detection by tandem mass spectrometry. Extraction of the serum samples is done by using acetonitrile. Estimates of precision for PFOA were generally within 610% for multiple replicates over the range of 0.5-40 ng/mL with a more precise relative precision measure of approximately 1% for highly fortified (10,000 ng/mL) samples. Relative precision estimates for PFOS were similar. Blood samples were not required to be fasting and were obtained at any time that the participants came to the study site, that is, throughout the course of the day. Serum was separated from red cells, placed in transport tubes, and refrigerated for shipment to the lab. Total cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides were measured enyzmatically at a large commercial accredited laboratory. Low density lipoprotein (LDL) cholesterol was calculated by the Friedewald equation when triglycerides were less than 400 mg/dL (94% of triglycerides).
Statistical analysis
Analyses were conducted by linear regression in which the outcomes were total cholesterol, LDL cholesterol, HDL cholesterol, the ratio of total cholesterol to HDL cholesterol, triglycerides, and non-HDL cholesterol (equal to total cholesterol À HDL cholesterol). We used (natural) log-transformed values of these variables for all outcomes, which tended to normalize residuals and led to a better goodness of fit as measured by the R-square. The improvement was particularly notable for the ratio of total cholesterol to HDL cholesterol and for triglycerides, which had the least normal distributions. For other outcomes, there was only a slight improvement, but we log transformed all outcomes for consistency. The log-transform model, when transformed back to the original scale, results in a multiplicative model in which the effects of PFOA and other covariates multiply the background cholesterol level.
Covariates in the model were chosen because of their established relation to 1 or more lipids (independent of whether they were associated with PFOA), such that they were potentially confounding variables. Covariates included age (8 categories), gender, body mass index (by quartile), education as a measure of socioeconomic status (less than high school, high school, more than high school), smoking (current, former, never), regular exercise (yes/no), and current alcohol consumption (yes/no). For simplicity, we retained the same set of covariates in all models. Covariates chosen in this manner were generally statistically significant predictors of most lipid outcomes, in the anticipated direction. We also considered a variable for fasting in the 6 hours prior to the blood sample (42% had not eaten in the prior 6 hours). This variable had little effect on any outcome other than triglycerides, where fasters had markedly lower triglyceride levels than did nonfasters. Hence, we included this variable in the triglyceride model. We also ran models separately for fasters and nonfasters to determine if the effects of PFOA and PFOS on outcomes differed by fasting status. Finally, we ran models for non-HDL cholesterol as this measure is less susceptible to postprandial effects (17) . PFOA and PFOS in all these analyses were considered as categorical (deciles) or continuous (sometimes (natural) log transformed) variables.
In addition to the linear regressions described above, we also ran a logistic model for the dichotomous outcome hypercholesterolemia, which was defined as a cholesterol level of !240 mg/dL (15% of the population had hypercholesterolemia). In these models, we used quartiles of PFOA (0-13.1, 13.2-26.5, 26.6-66.9, !67.0 ng/mL) or PFOS (0-13.2, 13.3-19.5, 19.6-28.0, !28.1 ng/mL), as well as models in which the exposures were continuous.
Graphical representation of the linear regression results focused on the predicted trend in lipids by decile (using the medians of the deciles) of either PFOA or PFOS, given a covariate profile for an average subject. Confidence intervals for predicted values were calculated for the expected population mean cholesterol level (SAS PROC REG, CML option; SAS Institute, Inc., Cary, North Carolina). Tests for linear trend in decile analyses were conducted on the basis of the P value for a single unlogged term for either PFOA or PFOS. Table 1 provides descriptive statistics on PFOA, PFOS, and outcome variables. As expected, PFOA was highly skewed, with some very high levels, while PFOS was not. Among the outcome variables, triglycerides were the most skewed. Missing data were minimal with the exception of LDL cholesterol for which 7% of subjects were missing, largely because of the exclusion of subjects with high triglycerides (>400 mg/dL). PFOA and PFOS were moderately correlated, with a Spearman correlation coefficient of 0.32. Table 2 gives descriptive statistics for other variables in the model, along with the percentage of missing data for each variable.
RESULTS
Descriptive results
Linear regression results; categorical exposure
A largely monotonic increase in log cholesterol with each decile of PFOA or PFOS was observed (Table 3; Figures 2 and 3). For both perfluorinated compounds, the exposure-response slope appears to decrease somewhat after about 40 ng/mL, although for PFOS this tendency is driven by only the last data point. The models each explained 14% of the variance of log cholesterol. Tests for linear trend were highly significant (Table 4) . Figures 4-8 display the results from the regression models in which PFOA and PFOS were considered as categorical variables in relation to lipids other than cholesterol.
Trends for LDL cholesterol, non-HDL cholesterol, and the ratio of total cholesterol to HDL cholesterol were similar to the nearly monotonic trends for total cholesterol seen in Figures 2 and 3 for total cholesterol for both perfluorinated compounds. There was also a positive trend between PFOA Median PFOS, ng/mL Predicted Total Cholesterol, mg/dL and triglycerides. There was little apparent association between either perfluorinated compound and HDL cholesterol. The R-squares for these models were 10%, 17%, 27%, 18%, and 26% for LDL cholesterol, non-HDL cholesterol, HDL cholesterol, triglycerides, and the ratio of total cholesterol to HDL cholesterol, respectively. Generally, the same trends with PFOA or PFOS were apparent for all lipid outcomes when the population was divided between fasters and nonfasters.
Linear regression results, continuous exposure
Results for linear regression analyses by using a continuous variable, with or without log transformation, for both PFOA and PFOS are given in Table 4 . The results for unlogged PFOA and PFOS are tests for linear trend for the categorical models; all such linear trends were positive and significant at the 0.05 level except for HDL cholesterol.
Considering both perfluorinated compounds as continuous variables, for most outcomes a model using the log transform of PFOA or PFOS fits the data better than one using untransformed PFOA or PFOS. This is consistent with the tailing off of the exposure-response curve at high exposures, seen for several outcomes.
When both PFOA and PFOS were considered together in the same model for total cholesterol, the effect of each was attenuated (20%-30%), but both continued to show the same monotonic, or nearly monotonic, trend of increasing cholesterol with increasing fluorocarbon.
Logistic regression results
The odds ratios for high cholesterol (total cholesterol, !240 mg/dL) in logistic regression models, by increasing quartile of PFOA, were 1.00 (referent), 1.21 (95% confidence interval (CI): 1.12, 1.31), 1.33 (95% CI: 1.23, 1.43), and 1.38 (95% CI: 1.28, 1.50). The corresponding adjusted odds ratios by quartile of PFOS were 1.00, 1.14 (95% CI: 1.05, 1.23), 1.28 (95% CI: 1.19, 1.39), and 1.51 (95% CI: 1.40, 1.64). Tests for linear trend, via use of a continuous term for PFOA and PFOS in these models, were highly significant (P < 0.0001 for both fluorocarbons).
Supplementary analyses
We conducted further analyses of 10,746 adults (19% of all adults) taking cholesterol-lowering medication, who had a mean cholesterol level of 173 mg/dL (vs. 206 mg/dL for those not taking cholesterol medication). In linear regression analyses, there was again a consistent increasing trend in total cholesterol with increasing PFOA (although somewhat attenuated compared with the exposure-response relation among those not taking medication) but no consistent trend for PFOS. We ran additional analyses for 2 other perfluorinated compounds, perfluorononanoic acid (PFNA) and perfluorohexanylsulfonate (PFHxS), for which we had almost complete data. These compounds are also present in the environment; they are not metabolites of PFOA and PFOS in the body. Both compounds were present at low levels in 99% of our population (mean PFNA, 1.6 ng/mL (standard deviation, 0.8); mean PFHxS, 5.1 ng/mL (standard deviation, 10.0)). Like PFOA and PFOS, both showed a monotonic increase in cholesterol by increasing decile of each perfluorinated compound. In part, a parallel exposureresponse pattern would be expected because both PFNA and PFHxS are, in turn, correlated with PFOA and PFOS (PFNA Spearman correlations ¼ 0.31 and 0.55 with PFOA and PFOS, respectively; PFNA Spearman correlations ¼ 0.31 and 0.47 with PFOA and PFOS, respectively), making it difficult to sort out the role of each specific perfluorinated compound.
We conducted supplementary analyses to explore possible interactions with gender and age, as well as the possible role of body mass index as an intermediate variable. We ran separate models for men and women for total cholesterol and PFOA or PFOS. Both sexes show monotonic increases in cholesterol with increases in both perfluorinated compounds, similar to the combined analyses. A test of interaction between gender and both log PFOA and log PFOS was not significant (P ¼ 0.16 and P ¼ 0.44, respectively). Similarly, we modeled interaction terms for categorical age and log PFOA and PFOS. An F test comparing the full model with interaction terms with a reduced model without them was not significant for either exposure (P ¼ 0.14 for both PFOA and PFOS), indicating slight interaction with age. We also ran models with or without body mass index in the model, under the hypothesis that body mass index might be an intermediate variable that should not be included in the model. Models without body mass index reduced the exposure coefficient for log PFOA by 8% and that for log PFOS by 2%.
We also ran an analysis including all subjects regardless of whether they were taking cholesterol medication, where the outcome was log PFOA (or log PFOS), and the predictor of interest was cholesterol medication. The motivation for this analysis was to assess whether taking cholesterol medication would be associated with lower PFOA, which might argue for ''reverse causality'' in that a decrease in cholesterol might lead to a decrease in PFOA. The model for log PFOA was taken from previous work (14) and included strong predictors including residential area and whether subjects worked at DuPont, as well as gender, age, body mass index, race, and other variables; this model explained 55% of the variance in log PFOA. Those taking cholesterol medication did, indeed, have a significantly lower log PFOA, but the effect was very modest (a decrease of only 4%), with statistical significance primarily a function of the large sample size. There was no difference in PFOS levels between those taking and not taking medication.
DISCUSSION
PFOA has been found to be positively correlated with cholesterol in 5 occupational studies (7-9, 11, 12 ) and 1 community study (10) , although in several of these the relation was not statistically significant at the 0.05 level. All of these studies except 1 were cross-sectional. Many showed a positive relation with other lipids, with the exception of HDL cholesterol.
These findings of increased cholesterol in humans contradict what would be expected from animal studies. In animals, PFOA is a strong peroxisome proliferator-activated Confidence intervals are based on the predicted population mean given those covariate levels. This model contained an additional variable for not having eaten in the 6 hours before blood draw; the figure is for an ''average'' subject who had not eaten in the past 6 hours. receptor-alpha in the liver, and this proliferation has been shown to alter lipid metabolism, resulting in decreases, not increases, in serum lipids (3, 18) . However, it is not known if this mechanism is relevant to humans, where peroxisome proliferation is generally less apparent (19) .
Our findings are broadly consistent with those from prior studies, using the largest data set to date. Both PFOA and PFOS showed largely consistent positive trends with all lipids except HDL cholesterol. The predicted increase in total cholesterol from lowest to highest decile of PFOA and PFOS was about 11-12 mg/dL. Analogously, the odds of high cholesterol (!240 mg/dL) increased 40%-50% from the lowest to the highest quartile of PFOA and PFOS serum levels. These differences are important when considering the large populations potentially affected. For example, in the Framingham population, high cholesterol (>240 mg/dL vs. <200 mg/dL) resulted in a relative risk of coronary heart disease of about 1.8 (20) . The finding that both PFOA (present at levels considerably above the US background) and PFOS (present at US background levels) were correlated independently with lipid levels suggests that perfluorinated compounds in general may show such associations.
The ratio of total cholesterol to HDL cholesterol also showed positive consistent trends in our data with both PFOS and PFOS. The ratio of total cholesterol to HDL cholesterol has been considered a better predictor of heart disease than total cholesterol itself, and there is continued evidence that this remains so (21) . Recently, the ratio of LDL cholesterol to HDL cholesterol has been advocated as the best predictor of heart disease (22) . The latter measure is highly correlated in our data to the ratio of total cholesterol to HDL cholesterol (Spearman correlation ¼ 0.94).
Interpretation of these data is made difficult by our cross-sectional design, which prohibits knowing whether an increase in cholesterol followed an increase in PFOA or PFOS. The mechanism by which these perfluorinated compounds might be related to cholesterol in humans is not known. Perfluorinated compounds are not lipophilic. However, it is possible that both cholesterol and the perfluorinated compounds are correlated with a third unknown substance that increases with lipids, for example, and it is even possible that increased lipids could lead to increased retention of PFOA/PFOS in the serum, that is, exhibiting ''reverse causality.'' Our analysis of PFOA levels in those taking cholesterol medications did not provide much evidence for reverse causality; while those on medication had lower PFOA, the decrease was only 4%. We will investigate further whether there is a casual relation between PFOA and cholesterol via a follow-up study of a subsample of this population in which we will retest subjects for cholesterol and PFOA/PFOS (refer to c8sciencepanel.org). PFOA levels are expected to have dropped because of filtration of the public water in [2005] [2006] . If cholesterol levels are unchanged when PFOA has decreased significantly, this would be evidence against causality, at least in terms of a short-term causal effect.
Another limitation of our analysis is the lack of a measure of cumulative exposure to PFOA or PFOS. We are in the process of estimating such measures in a separate project, using PFOA emissions from the plant over time, combined with residential history, data on wind patterns and groundwater flow, and pharmacokinetic modeling (refer to c8sci-encepanel.org). Results from this project are not yet available.
It should be noted that, although PFOA and PFOS are highly significant predictors of lipid levels (our study had high power to detect statistically significant differences, compared with prior smaller studies), the perfluorinated compounds themselves did not explain a large portion of the variance in lipids. For total cholesterol, the most important predictors were age, gender, and body mass index, not serum levels of PFOA or PFOS.
Despite the caveats above, our findings are a cause for concern, given that both PFOA and PFOS are widespread in the serum of virtually all Americans and are common in many countries worldwide (23) . If a causal relation between perfluorinated compound levels and cholesterol exists, there could be potentially serious consequences in the form of increased risk of cardiovascular disease. Published data to date are inadequate to establish whether PFOA increases the risk of heart disease. Existing studies have been restricted to mortality studies of US worker populations (24, 25) , with limited sample size and without clear results. We are conducting a longitudinal study of the population studied here to further investigate a possible relation between PFOA and PFOS and cardiovascular and other diseases (refer to c8sci-encepanel.org for details).
